SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?
Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.
Pharma & Biotech
Pharma & Biotech
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.
Pharma & Biotech
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.
Pharma & Biotech
What Zai Lab’s latest oncology data reveal about its long-term positioning in ADC and immunotherapy markets
Zai Lab presents new oncology data at AACR 2026. Discover what its ADC and immunotherapy pipeline could mean for future cancer treatment strategies.
Pharma & Biotech
Biocytogen and IDEAYA Biosciences push IDE034 into the clinic as dual-antigen ADC strategies mature
IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.
Pharma & Biotech
Can BioAtla’s Oz-V set a new standard in ROR2-targeted therapy for head and neck cancer?
BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.